Barclays Reports 18 Profit Increase and Lifts FullYear Income Forecast US and Iran Signal Potential Progress in Talks but Key Disputes Over Uranium and Strait of Hormuz Tolls Remain April Jobs Report Preview Labor Market Shows Cooling but Resilient Trends 1100 Architect Named to Forbes Americas Top Architects 2025 List Unveils Bold BostonArea Project Puig Shares Slide as Este Lauder Collaboration Discussions End European Markets Edge Higher UKGulf Trade Deal Hailed as Monumental Achievement by Bahrain Minister Implications for Bilateral Commerce PRTC Q4 2024 Earnings EPS Misses Estimates as Pipeline Progress Continues Safe Pro Group Inc SPAI Q1 2026 Earnings WiderthanExpected Loss Reflects Investment Phase The Kraft Heinz Company KHC Q1 2026 Earnings EPS Surprises to the Upside Amidst Operational Resilience BHP Q1 2026 Earnings EPS Misses Estimates Yet Stock Gains on Operational Resilience SCL Q1 2026 Earnings Slight EPS Beat Drives Positive Market Response LH Q1 2026 Earnings Labcorp Beats EPS Estimates but Stock Slips Slightly DMC Global BOOM Surges 478 Key Levels and Market Dynamics ENJ Bonds Edge Higher as Entergy New Orleans 50 Series Approaches Resistance Steady Demand in FixedIncome Market Ohio Valley Banc Corp OVBC Holds Steady Near Support as Volume Remains Tame Flaherty Crumrine Total Return Fund FLC Holds Steady Near Key Support as YieldSeeking Investors Weigh Options Nabors Industries NBR Slips Nearly 3 as Oilfield Services Face Headwinds Huntington Bancshares HBANZ Q1 2026 Earnings Preferred Stock EPS Falls Short of Estimates Amid Narrowing Net Interest Margin FSS Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction PMTV Q1 2026 Earnings Persistent Headwinds Trigger Significant EPS Miss RHP Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction SRPT Q1 2026 Earnings EPS Surges 18467 Above Estimates Amid Strong Gene Therapy Progress IXICO Contract Wins Signal Strong Revenue Visibility for Current Fiscal Year BLDR Q1 2026 Earnings EPS Misses Estimates by 284 Stock Edges Higher AgomAb Therapeutics AGMB Advances 317 as Biotech Stock Nears Key Resistance